messaggio

clik on the image and visit the new site

New site clik on the image

"In silico"


From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.


Phage Therapy is influenced by:

Phage therapy is influenced by:

Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
Mutation rate
Phenotypical delay
Phage cocktail

My point of view

Monday, 1 November 2010

The Isolation and Characterization of Novel Mycobacteriophages

From: University of Tennessee Honors Program

Honors Thesis Projects

University of Tennessee, Knoxville Year 2004

The Isolation and Characterization of Novel Mycobacteriophages

Elizabeth Ann Fleming

University of Tennessee - Knoxville




"Conclusion

Although none of the new phages isolated were lytic for M. ulcerans, two known phages, D29 and Bxz2, were lytic. It is not surprising that D29 was one of the two phages able to infect M ulcerans because the established host range for D29 is very large and includes both slow and fast-growing species. Jan Rybniker continued to study D29 by carrying out experiments, which tested its ability to be used as phage therapy in animal models infected with M. ulcerans...."

Go here(a)

Go here(b)

Mycobacteriophage Proteomes comparison
(my contribution: four "in silico " proteome simulations in a single superimposing of pictures)